cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biological Therapy
Autologous antitumor lymphocytes regress metastatic melanoma in cancer patients
December 14th, 2004
Autologous antitumor lymphocytes regress metastatic melanoma in cancer patients. According to scientists in the United States, "our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (50% reduction in tumor), including four complete responders." "In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in...
Source: cancer weekly (2004-12-14)
|
